Stem Cell Transplant Program, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Front Immunol. 2021 May 19;12:641427. doi: 10.3389/fimmu.2021.641427. eCollection 2021.
Endothelial cell (EC) dysfunction causes a number of early and life-threatening post hematopoietic stem cell transplant (HCT) complications that result in a rapid clinical decline. The main early complications are graft-.-host disease (GVHD), transplant associated thrombotic microangiopathy (TA-TMA), and sinusoidal obstruction syndrome (SOS). Post-HCT endothelial dysfunction occurs as a result of chemotherapy, infections, and allogeneic reactivity. Despite major advances in transplant immunology and improvements in supportive care medicine, these complications represent a major obstacle for successful HCT. In recent years, different biomarkers have been investigated for early detection of post-transplant endothelial cell dysfunction, but few have been validated. In this review we will define GVHD, TA-TMA and SOS, summarize the current data available in HCT biomarker research and identify promising biomarkers for detection and diagnosis of early HCT complications.
内皮细胞 (EC) 功能障碍会导致许多造血干细胞移植 (HCT) 后早期和危及生命的并发症，导致快速临床恶化。主要的早期并发症包括移植物抗宿主病 (GVHD)、移植相关血栓性微血管病 (TA-TMA) 和窦状隙阻塞综合征 (SOS)。HCT 后内皮功能障碍是由化疗、感染和同种异体反应引起的。尽管在移植免疫学方面取得了重大进展，并改善了支持治疗医学，但这些并发症仍是 HCT 成功的主要障碍。近年来，已经研究了不同的生物标志物来早期检测移植后内皮细胞功能障碍，但很少有得到验证。在这篇综述中，我们将定义 GVHD、TA-TMA 和 SOS，总结 HCT 生物标志物研究中现有的数据，并确定有希望用于检测和诊断早期 HCT 并发症的生物标志物。
